DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04165837 (ClinicalTrials.gov)	October 14, 2019	13/11/2019	Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects	Parkinson's Disease	Drug: FB-101;Drug: Placebo	1ST Biotherapeutics, Inc.	NULL	Recruiting	19 Years	55 Years	All	48	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04165837
(ClinicalTrials.gov)

October 14, 2019

13/11/2019

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

Parkinson's Disease

Drug: FB-101;Drug: Placebo

1ST Biotherapeutics, Inc.

NULL

Recruiting

19 Years

55 Years

All

Phase 1

United States